Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis. The QTDP grant program provides support for innovative projects that are determined to have reasonable potential to result in new therapies and reduce health care costs.  

"We are pleased to be awarded these two QTDP grants. Our research, academic collaborations and discoveries promise to advance the understanding of and ability to better manage today's most important medical challenges," said Lewis H. Bender, CEO, Interleukin Genetics. "We remain steadfast in our commitment to developing genetic tests for major areas with unmet needs."

The Patient Protection and Affordable Care Act of 2010 made available $1.0 billion in QTDP Program funding to cover certain costs paid or incurred in calendar 2009 and 2010 directly related to the conduct of a qualifying project. The Department of Health and Human Services (HHS) designates such projects based on the potential to produce new cost-saving therapies, support jobs and increase U.S. competitiveness.